Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BEAM NASDAQ:DNLI NASDAQ:KURA NYSE:RCUS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBEAMBeam Therapeutics$29.03-1.3%$29.41$15.60▼$36.44$3.03B2.251.82 million shs1.59 million shsDNLIDenali Therapeutics$21.66+3.0%$19.80$12.58▼$23.77$3.34B1.031.80 million shs2.18 million shsKURAKura Oncology$9.05+2.1%$9.31$5.45▼$12.49$786.54M0.362.20 million shs1.30 million shsRCUSArcus Biosciences$23.85+2.4%$24.05$7.91▼$28.72$2.93B0.851.00 million shs1.45 million shs7 Stocks to Buy Before the Robotics RevolutionRobotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming to the United States, and there are four ways that investors can gain exposure to this new robotics revolution. Plus, learn which seven companies are most positioned to benefit as intelligent robots enter the workforce. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBEAMBeam Therapeutics-0.27%-10.44%-6.87%+16.89%+64.39%DNLIDenali Therapeutics+1.99%+4.37%+8.02%+2.19%+38.38%KURAKura Oncology+2.07%+1.03%-8.47%+2.43%+28.03%RCUSArcus Biosciences+5.02%-5.90%-6.25%+6.58%+157.20%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBEAMBeam Therapeutics$29.03-1.3%$29.41$15.60▼$36.44$3.03B2.251.82 million shs1.59 million shsDNLIDenali Therapeutics$21.66+3.0%$19.80$12.58▼$23.77$3.34B1.031.80 million shs2.18 million shsKURAKura Oncology$9.05+2.1%$9.31$5.45▼$12.49$786.54M0.362.20 million shs1.30 million shsRCUSArcus Biosciences$23.85+2.4%$24.05$7.91▼$28.72$2.93B0.851.00 million shs1.45 million shs7 Stocks to Buy Before the Robotics RevolutionRobotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming to the United States, and there are four ways that investors can gain exposure to this new robotics revolution. Plus, learn which seven companies are most positioned to benefit as intelligent robots enter the workforce. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBEAMBeam Therapeutics-0.27%-10.44%-6.87%+16.89%+64.39%DNLIDenali Therapeutics+1.99%+4.37%+8.02%+2.19%+38.38%KURAKura Oncology+2.07%+1.03%-8.47%+2.43%+28.03%RCUSArcus Biosciences+5.02%-5.90%-6.25%+6.58%+157.20%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBEAMBeam Therapeutics 2.71Moderate Buy$46.8361.33% UpsideDNLIDenali Therapeutics 2.87Moderate Buy$34.2558.13% UpsideKURAKura Oncology 2.69Moderate Buy$25.58182.69% UpsideRCUSArcus Biosciences 2.58Moderate Buy$35.1047.17% UpsideCurrent Analyst Ratings BreakdownLatest KURA, DNLI, BEAM, and RCUS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/4/2026KURAKura Oncology Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight6/4/2026KURAKura Oncology CLSASubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$24.006/4/2026KURAKura Oncology Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$24.006/4/2026RCUSArcus Biosciences Lifesci CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$46.005/28/2026KURAKura Oncology OppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$24.005/28/2026KURAKura Oncology Jefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$24.005/28/2026KURAKura Oncology CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingMarket Outperform5/22/2026DNLIDenali Therapeutics Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$40.00 ➝ $35.005/22/2026DNLIDenali Therapeutics Deutsche Bank AktiengesellschaftSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$31.005/21/2026BEAMBeam Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$80.005/18/2026RCUSArcus Biosciences Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$30.00 ➝ $35.00(Data available from 6/12/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBEAMBeam Therapeutics$139.74M21.37N/AN/A$12.20 per share2.38DNLIDenali Therapeutics$330.53M10.40N/AN/A$6.91 per share3.13KURAKura Oncology$67.48M11.91N/AN/A$2.00 per share4.53RCUSArcus Biosciences$247M12.14N/AN/A$5.84 per share4.08Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBEAMBeam Therapeutics-$79.99M-$0.68N/AN/AN/A-39.66%-29.00%-22.61%8/4/2026 (Estimated)DNLIDenali Therapeutics-$512.54M-$2.88N/AN/AN/AN/A-52.20%-43.86%8/10/2026 (Estimated)KURAKura Oncology-$278.67M-$3.35N/AN/AN/A-411.19%-141.95%-43.28%8/6/2026 (Estimated)RCUSArcus Biosciences-$353M-$3.18N/AN/AN/A-156.36%-68.97%-35.27%8/5/2026 (Estimated)Latest KURA, DNLI, BEAM, and RCUS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2026Q1 2026KURAKura Oncology-$0.88-$0.83+$0.05-$0.83$25.97 million$18.27 million5/7/2026Q1 2026BEAMBeam Therapeutics-$1.0278-$0.91+$0.1178-$0.91$10.98 million$31.74 million5/7/2026Q1 2026DNLIDenali Therapeutics-$0.73-$0.69+$0.04-$0.69$2.57 millionN/A5/5/2026Q1 2026RCUSArcus Biosciences-$0.92-$1.02-$0.10-$1.02$29.49 million$17.00 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthBEAMBeam TherapeuticsN/AN/AN/AN/AN/ADNLIDenali TherapeuticsN/AN/AN/AN/AN/AKURAKura OncologyN/AN/AN/AN/AN/ARCUSArcus BiosciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBEAMBeam Therapeutics0.0916.9916.99DNLIDenali Therapeutics0.019.289.28KURAKura Oncology0.096.156.14RCUSArcus Biosciences0.194.044.04Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBEAMBeam Therapeutics99.68%DNLIDenali Therapeutics92.92%KURAKura OncologyN/ARCUSArcus Biosciences92.89%Insider OwnershipCompanyInsider OwnershipBEAMBeam Therapeutics3.80%DNLIDenali Therapeutics12.50%KURAKura Oncology7.60%RCUSArcus Biosciences9.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBEAMBeam Therapeutics510102.88 million98.97 millionOptionableDNLIDenali Therapeutics430158.71 million138.87 millionOptionableKURAKura Oncology13088.77 million82.03 millionOptionableRCUSArcus Biosciences500125.77 million113.70 millionOptionableKURA, DNLI, BEAM, and RCUS HeadlinesRecent News About These CompaniesArcus Biosciences Stockholders Back Directors and Governance Measures4 hours ago | tipranks.comArcus Biosciences Advances Casdatifan With New Phase 1 Bioequivalence StudyJune 11 at 12:50 PM | tipranks.comArcus Biosciences, Inc. (RCUS) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 TranscriptJune 9 at 10:05 PM | seekingalpha.comArcus Biosciences Announces New Employment Inducement GrantsJune 9 at 4:35 PM | businesswire.comArcus Biosciences, Inc. (RCUS) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 - SlideshowJune 9 at 1:02 PM | seekingalpha.comArcus Biosciences, Inc. $RCUS Shares Acquired by BNP Paribas Financial MarketsJune 9 at 3:17 AM | marketbeat.comArcus Biosciences, Inc. (NYSE:RCUS) Receives Average Recommendation of "Moderate Buy" from AnalystsJune 8, 2026 | americanbankingnews.comArcus Biosciences, Inc. (NYSE:RCUS) Receives Consensus Recommendation of "Moderate Buy" from AnalystsJune 8, 2026 | marketbeat.comWhat is Lifesci Capital's Forecast for RCUS Q2 Earnings?June 8, 2026 | americanbankingnews.comQ2 Earnings Estimate for RCUS Issued By Lifesci CapitalJune 8, 2026 | marketbeat.comArcus, Bristol Myers Team Up to Advance Kidney Cancer StudyJune 4, 2026 | zacks.comLifesci Capital Initiates Coverage on Arcus Biosciences (NYSE:RCUS)June 4, 2026 | marketbeat.comArcus to Supply Experimental Kidney Cancer Drug for Myers Squibb TrialJune 3, 2026 | marketwatch.comArcus Biosciences Announces Clinical Trial Collaboration and Supply Agreement to Evaluate Casdatifan in Combination with PD‑L1/VEGF‑A Bispecific Immunomodulator to Treat Kidney CancerJune 3, 2026 | businesswire.comArcus Biosciences (NYSE:RCUS) CAO Sells $66,022.74 in StockJune 2, 2026 | insidertrades.comFisher Asset Management LLC Increases Position in Arcus Biosciences, Inc. $RCUSMay 27, 2026 | marketbeat.comArcus Biosciences to Participate in the Goldman Sachs 47th Annual Global Healthcare ConferenceMay 26, 2026 | businesswire.comArcus Biosciences, Inc. $RCUS Shares Sold by Sectoral Asset Management Inc.May 25, 2026 | marketbeat.comNewsflash: Arcus Biosciences, Inc. (NYSE:RCUS) Analysts Have Been Trimming Their Revenue ForecastsMay 17, 2026 | finance.yahoo.comArcus Biosciences (NYSE:RCUS) CFO Sells $198,965.69 in StockMay 13, 2026 | insidertrades.comAnalyst Estimates: Here's What Brokers Think Of Arcus Biosciences, Inc. (NYSE:RCUS) After Its First-Quarter ReportMay 9, 2026 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesSpaceX Gets the Attention, But These 4 Stocks Could Get the ReturnsBy Bridget Bennett | May 25, 20265 Stocks Winning the AI Race While Everyone Watches NVIDIABy Bridget Bennett | May 26, 2026The Smart Glasses Gold Rush Is Leaving Old-School Eyewear BehindBy Jeffrey Neal Johnson | May 24, 20263 Space Infrastructure Stocks Gaining Momentum Ahead of the SpaceX IPOBy Ryan Hasson | May 20, 2026Aggressive Insider Buying Signals Opportunity in 3 Risky StocksBy Thomas Hughes | June 2, 2026KURA, DNLI, BEAM, and RCUS Company DescriptionsBeam Therapeutics NASDAQ:BEAM$29.03 -0.38 (-1.29%) Closing price 04:00 PM EasternExtended Trading$29.38 +0.34 (+1.19%) As of 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a. The company has research collaboration agreement with Pfizer Inc., focus on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Apellis Pharmaceuticals to conduct preclinical research on target specific genes within the complement system in various organs, including the eye, liver, and brain; Verve Therapeutics, Inc., for cardiovascular disease treatments; Sana Biotechnology, Inc., to research, develop, and commercialize rights to CRISPR Cas12b for cell therapy programs; and Orbital Therapeutics design RNA for the prevention, treatment or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.Denali Therapeutics NASDAQ:DNLI$21.66 +0.64 (+3.04%) Closing price 04:00 PM EasternExtended Trading$21.66 0.00 (0.00%) As of 07:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Denali Therapeutics Inc., a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2. Its brain-penetrant small molecule programs comprise BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; SAR443820/DNL788 RIPK1 inhibitor program for CNS disease; DNL343 eIF2B Activator program for amyotrophic lateral sclerosis; and SAR443122/DNL758 RIPK1 inhibitor program for peripheral inflammatory diseases. It also provides early stage program include TAK-594/DNL593 program for FTD-GRN; DNL126 program for MPS IIIA, a Sanfilippo Syndrome A; DNL622 for MPS I which is Hurler syndrome; Antibody Transport Vehicle Amyloid beta program; Oligonucleotide Transport Vehicle platform, a novel class of biotherapeutics to address the root cause of diseases through modulation of gene expression; and other TV-enabled discovery programs. The company has collaboration agreements with Biogen MA Inc. and Biogen International GmbH; Genzyme Corporation; Takeda Pharmaceutical Company Limited; F-star Gamma Limited, F-star Biotechnologische Forschungs-und Entwicklungsges m.b.H, and F-star Biotechnology Limited; and Genentech, Inc. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.Kura Oncology NASDAQ:KURA$9.05 +0.19 (+2.14%) Closing price 04:00 PM EasternExtended Trading$9.06 +0.00 (+0.06%) As of 06:38 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors. It has a clinical collaboration with Novartis Pharma AG to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression and/or PIK3CA mutation and/or amplification. The company was founded in 2014 and is headquartered in San Diego, California.Arcus Biosciences NYSE:RCUS$23.85 +0.55 (+2.36%) Closing price 03:59 PM EasternExtended Trading$23.93 +0.08 (+0.34%) As of 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies. It also develops Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in Phase 2 clinical trial; Quemliclustat, a small-molecule CD73 inhibitor, which is Phase 1b and Phase 2 clinical trial; Zimberelimab, an anti-PD-1 antibody, which is in Phase 2 clinical trial for metastatic cell lung cancer and monotherapy; and AB521, an oral and small-molecule inhibitor of HIF-2a, which is in Phase 1 clinical trial for the treatment of Von Hippel-Lindau disease. In addition, the company's preclinical pipeline products include AB598, a CD39 antibody; and AB801, a small molecule Axl inhibitor. It has a clinical collaboration with AstraZeneca to evaluate domvanalimab in combination with durvalumab in a registrational phase 3 clinical trial in patients with unresectable Stage 3 NSCLC; and BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases. Arcus Biosciences, Inc. was incorporated in 2015 and is headquartered in Hayward, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas SpaceX Rings the Bell and Shatters Every Record Adobe Stock Just Got Cheaper—Is Wall Street Missing the Story? ERock IPO: A $1.3B Power Play Solution Boeing’s Unseen Rebound: Why the Headlines Are Wrong Why Oracle's 10% Drop May Be Telling the Wrong Story Spotify's "North Star" Outlook Was Music to Investors Ears DraftKings Hits the Jackpot With Super App Pivot Cracker Barrel Surges 23% as Earnings Beat Signals Turnaround Progress Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
